MLTX
MoonLake ImmunotherapeuticsNASDAQHealthcare$17.36+5.08%ClosedMarket Cap: $1.25B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.60
P/S
0.00
EV/EBITDA
-4.36
DCF Value
$4.08
FCF Yield
-16.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-67.1%
ROA
-53.6%
ROIC
-64.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-65.2M | $-62.4M | $-0.93 | — |
| FY 2025 | $0.00 | -Infinity% | $-244.8M | $-227.3M | $-3.53 | — |
| Q3 2025 | $0.00 | -Infinity% | $-71.4M | $-69.7M | $-1.10 | — |
| Q2 2025 | $0.00 | -Infinity% | $-60.7M | $-55.2M | $-0.87 | — |
| Q1 2025 | $0.00 | NaN% | $-47.5M | $-39.9M | $-0.63 | — |
| Q4 2024 | $0.00 | NaN% | $-49.6M | $-45.6M | $-0.72 | — |
| FY 2024 | $0.00 | NaN% | $-143.1M | $-118.9M | $-1.89 | — |
| Q3 2024 | $0.00 | -Infinity% | $-43.1M | $-35.4M | $-0.56 | — |
| Q2 2024 | $0.00 | NaN% | $-30.6M | $-24.3M | $-0.39 | — |
| Q1 2024 | $0.00 | NaN% | $-19.8M | $-13.7M | $-0.22 | — |
| Q4 2023 | $0.00 | NaN% | $-15.0M | $-7.4M | $-0.12 | — |
| FY 2023 | $0.00 | NaN% | $-54.1M | $-36.0M | $-0.73 | — |